AVEO Pharmaceuticals Articles

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial

4 January 2012

AVEO Pharma licenses RON-targeted antibodies to Johnson & Johnson unit for up to $555 million

1 June 2011

New president and CEO at Astellas Pharma Europe and in USA; Ex-Genzyme CEO joins AVEO board

13 April 2011

Aveo set to earn more than $1.3 billion in licensing deal with Astellas for cancer drug tivozanib

17 February 2011

Merck & Co returns rights to HGF antibody candidate to AVEO Pharma and Caeylx to Johnson & Johnson

1 October 2010

AVEO Pharma gets $5 million milestone as Biogen selects first candidate under ErbB3 antibody program

15 April 2010

Showing 1-6 of 6 articles

Go to beginning

Previous

1

Next

Go to end